Stem Cell Clinic

Childrens Hospital Los Angeles Researchers Uncover New Clues to Origins of the Most Common Pediatric Kidney Cancer – Newswise

By Stell Cell Research

Newswise While Wilms tumoralso known as nephroblastoma-- is rare, it is the most prevalent childhood kidney cancer. Researchers at Childrens Hospital Los Angeles have now pinpointed a disruption in early kidney progenitor cell development that can be linked to the formation of Wilms tumor.

In a study published in Advanced Science, researchers at the GOFARR Laboratory in Urology compared kidney progenitor cells from a tumor with precursor cells from a healthy kidney. Normally, these precursor cells mature into kidney cells, but when their early development is dysregulated, they behave like cancer stem cells.

While most children with Wilms tumor are successfully treated, current therapies are aggressive. A minority of these patients have unfavorable prognoses or relapses; for these children, there is no existing therapy. By achieving a more precise understanding of how Wilms tumors develop, our goal is to find new treatments for all types of Wilms tumor, says Laura Perin, PhD, Co-Director of the GOFARR laboratory and senior study co-author with Stefano Da Sacco, PhD, another researcher at the GOFARR Laboratory.

Pediatric Wilms tumor can be considered a developmental cancer, says Dr. Perin, who is also Associate Professor at the Keck School of Medicine of USC. The normal adult kidney lacks kidney precursor cells, as they are exhausted before birth. But in Wilms tumors, instead of giving rise to a functional kidney, these precursor cells persist and form the tumor mass.

The researchers characterized these Wilms tumor kidney precursor cells, finding that these cells can reproduce the original tumor. They are aggressive, theyre drug-resistant, they metastasize like cancer cells, and they are able to create the full tumor that we see in patients, says Astgik Petrosyan, PhD, researcher at the GOFARR Lab and first author of the study.

The kidney precursor cells that generate Wilms tumors also abnormally expressed ITG1 and ITG4, proteins that help cells communicate with their microenvironment. This abnormal attachment to their microenvironment favors the uncontrolled replication of these cells and guides the formation of the tumor mass, says Dr. Da Sacco.

"Our findings provide a more accurate understanding of the different stages of both normal and abnormal kidney development, says Dr. Perin. This can possibly help the diagnosis of Wilms tumor, leading to more effective treatments for these patients.

Other study co-authors include: Valentina Villania, PhD, of CHLA; Paola Aguiari, PhD, of CHLA and David Geffen School of Medicine at UCLA - VA Healthcare System; Matthew E. Thornton, MS, of the Keck School of Medicine of USC; Yizhou

Wang, PhD, and Alex Rajewski, PhD, of Cedars-Sinai Medical Center; Shengmei Zhou, MD, of CHLA, Paolo Cravedi, MD, PhD of the Icahn School of Medicine at Mount Sinai; Brendan H. Grubbs, MD, of the Keck School of Medicine of USC; Roger E. De Filippo, MD, Sargis Sedrakyan, PhD and Kevin V. Lemley, MD, PhD, of CHLA and the Keck School of Medicine at USC; and Marie Csete, MD, PhD of USC.

About Childrens Hospital Los Angeles

Childrens Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country and the greater Southern California region. Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No. 1 pediatric hospital in the Pacific region and California, and among the top 10 in the nation on U.S. News & World Reports Honor Roll of Best Childrens Hospitals. Clinical expertise spans the pediatric care continuum for newborns to young adults, from everyday preventive medicine to the most advanced cases. Inclusive, kid- and family-friendly clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC, and proven discoveries reach patients faster through The Saban Research Institute of Childrens Hospital Los Angelesamong the top 10 childrens hospitals for National Institutes of Health funding. The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the western United States. To learn more, follow us onFacebook,Instagram,LinkedIn,YouTubeandTwitter, and visit our blog atCHLA.org/blog.

Read this article:
Childrens Hospital Los Angeles Researchers Uncover New Clues to Origins of the Most Common Pediatric Kidney Cancer - Newswise

Uncovering the transcriptional regulatory network involved in … – Nature.com

By Stell Cell Research

Haberlandt, G. in Plant Tissue Culture: 100 Years Since Gottlieb Haberlandt (eds Laimer, M. & Rcker, W.) 124 (Springer, 2003); https://doi.org/10.1007/978-3-7091-6040-4_1

Bidabadi, S. S. & Jain, S. M. Cellular, molecular, and physiological aspects of in vitro plant regeneration. Plants 9, 702 (2020).

Article CAS PubMed PubMed Central Google Scholar

Thorpe, T. A. History of plant tissue culture. Mol. Biotechnol. 37, 169180 (2007).

Article CAS PubMed Google Scholar

Radhakrishnan, D. et al. Shoot regeneration: a journey from acquisition of competence to completion. Curr. Opin. Plant Biol. 41, 2331 (2018).

Article CAS PubMed Google Scholar

Shin, J., Bae, S. & Seo, P. J. De novo shoot organogenesis during plant regeneration. J. Exp. Bot. 71, 6372 (2019).

Article Google Scholar

Hayta, S. et al. An efficient and reproducible Agrobacterium-mediated transformation method for hexaploid wheat (Triticum aestivum L.). Plant Methods 15, 121 (2019).

Article CAS PubMed PubMed Central Google Scholar

Ikeuchi, M. et al. Molecular mechanisms of plant regeneration. Annu. Rev. Plant Biol. 70, 377406 (2019).

Article CAS PubMed Google Scholar

Hu, B. et al. Divergent regeneration-competent cells adopt a common mechanism for callus initiation in angiosperms. Regeneration 4, 132139 (2017).

Article CAS PubMed PubMed Central Google Scholar

Atta, R. et al. Pluripotency of Arabidopsis xylem pericycle underlies shoot regeneration from root and hypocotyl explants grown in vitro. Plant J. 57, 626644 (2009).

Article CAS PubMed Google Scholar

Sugimoto, K., Jiao, Y. & Meyerowitz, E. M. Arabidopsis regeneration from multiple tissues occurs via a root development pathway. Dev. Cell 18, 463471 (2010).

Article CAS PubMed Google Scholar

Hu, X. & Xu, L. Transcription factors WOX11/12 directly activate WOX5/7 to promote root primordia initiation and organogenesis. Plant Physiol. 172, 23632373 (2016).

Article CAS PubMed PubMed Central Google Scholar

Liu, J. et al. The WOX11-LBD16 pathway promotes pluripotency acquisition in callus cells during de novo shoot regeneration in tissue culture. Plant Cell Physiol. 59, 734743 (2018).

Article PubMed Google Scholar

Liu, J. et al. WOX11 and 12 are involved in the first-step cell fate transition during de novo root organogenesis in Arabidopsis. Plant Cell 26, 10811093 (2014).

Article CAS PubMed PubMed Central Google Scholar

Gordon, S. P. et al. Pattern formation during de novo assembly of the Arabidopsis shoot meristem. Development 134, 35393548 (2007).

Article CAS PubMed Google Scholar

Meng, W. J. et al. Type-B ARABIDOPSIS RESPONSE REGULATORs specify the shoot stem cell niche by dual regulation of WUSCHEL. Plant Cell 29, 13571372 (2017).

Article CAS PubMed PubMed Central Google Scholar

Kareem, A. et al. PLETHORA genes control regeneration by a two-step mechanism. Curr. Biol. 25, 10171030 (2015).

Article CAS PubMed PubMed Central Google Scholar

Liu, X., Zhu, K. & Xiao, J. Recent advances in understanding of the epigenetic regulation of plant regeneration. aBIOTECH https://doi.org/10.1007/s42994-022-00093-2 (2023).

He, C., Chen, X., Huang, H. & Xu, L. Reprogramming of H3K27me3 is critical for acquisition of pluripotency from cultured Arabidopsis tissues. PLoS Genet. 8, e1002911 (2012).

Article CAS PubMed PubMed Central Google Scholar

Lee, K., Park, O.-S. & Seo, P. J. Arabidopsis ATXR2 deposits H3K36me3 at the promoters of LBD genes to facilitate cellular dedifferentiation. Sci. Signal. 10, eaan0316 (2017).

Article PubMed Google Scholar

Lee, K. et al. Arabidopsis ATXR2 represses de novo shoot organogenesis in the transition from callus to shoot formation. Cell Rep. 37, 109980 (2021).

Article CAS PubMed Google Scholar

Lee, K., Park, O.-S., Choi, C. Y. & Seo, P. J. ARABIDOPSIS TRITHORAX 4 facilitates shoot identity establishment during the plant regeneration process. Plant Cell Physiol. 60, 826834 (2019).

Article CAS PubMed Google Scholar

Liu, H., Zhang, H., Dong, Y. X., Hao, Y. J. & Zhang, X. S. DNA METHYLTRANSFERASE1-mediated shoot regeneration is regulated by cytokinin-induced cell cycle in Arabidopsis. New Phytol. 217, 219232 (2018).

Article CAS PubMed Google Scholar

Hiei, Y., Ishida, Y. & Komari, T. Progress of cereal transformation technology mediated by Agrobacterium tumefaciens. Front. Plant Sci. 5, 628 (2014).

Article PubMed PubMed Central Google Scholar

Ishida, Y., Tsunashima, M., Hiei, Y. & Komari, T. Wheat (Triticum aestivum L.) transformation using immature embryos. Methods Mol. Biol. 1223, 189198 (2015).

Article CAS PubMed Google Scholar

Zhang, W. et al. Regeneration capacity evaluation of some largely popularized wheat varieties in China. Acta Agron. Sin. 44, 208217 (2018).

Article Google Scholar

Wang, K., Liu, H., Du, L. & Ye, X. Generation of marker-free transgenic hexaploid wheat via an Agrobacterium-mediated co-transformation strategy in commercial Chinese wheat varieties. Plant Biotechnol. J. 15, 614623 (2017).

Article CAS PubMed Google Scholar

Lowe, K. et al. Morphogenic regulators Baby boom and Wuschel improve monocot transformation. Plant Cell 28, 19982015 (2016).

Article CAS PubMed PubMed Central Google Scholar

Suo, J. et al. Identification of regulatory factors promoting embryogenic callus formation in barley through transcriptome analysis. BMC Plant Biol. 21, 145 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, K. et al. The gene TaWOX5 overcomes genotype dependency in wheat genetic transformation. Nat. Plants 8, 110117 (2022).

Article PubMed Google Scholar

Debernardi, J. M. et al. A GRF-GIF chimeric protein improves the regeneration efficiency of transgenic plants. Nat. Biotechnol. 38, 12741279 (2020).

Article CAS PubMed PubMed Central Google Scholar

Qiu, F. et al. Transient expression of a TaGRF4-TaGIF1 complex stimulates wheat regeneration and improves genome editing. Sci. China Life Sci. 65, 731738 (2022).

Article CAS PubMed Google Scholar

Zhao, L. et al. Dynamic chromatin regulatory programs during embryogenesis of hexaploid wheat. Genome Biol. 24, 7 (2023).

Article CAS PubMed PubMed Central Google Scholar

Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20, 207220 (2019).

Article CAS PubMed Google Scholar

Wang, M. et al. An atlas of wheat epigenetic regulatory elements reveals subgenome divergence in the regulation of development and stress responses. Plant Cell 33, 865881 (2021).

Article PubMed PubMed Central Google Scholar

Sarkar, A. K. et al. Conserved factors regulate signalling in Arabidopsis thaliana shoot and root stem cell organizers. Nature 446, 811814 (2007).

Article CAS PubMed Google Scholar

Yu, J., Liu, W., Liu, J., Qin, P. & Xu, L. Auxin control of root organogenesis from callus in tissue culture. Front. Plant Sci. 8, 1385 (2017).

Article PubMed PubMed Central Google Scholar

Della Rovere, F. et al. Auxin and cytokinin control formation of the quiescent centre in the adventitious root apex of Arabidopsis. Ann. Bot. 112, 13951407 (2013).

Article PubMed PubMed Central Google Scholar

Wu, L. Y. et al. Dynamic chromatin state profiling reveals regulatory roles of auxin and cytokinin in shoot regeneration. Dev. Cell 57, 526542 (2022).

Article CAS PubMed Google Scholar

Ikeuchi, M. et al. A gene regulatory network for cellular reprogramming in plant regeneration. Plant Cell Physiol. 59, 770782 (2018).

Article CAS PubMed Central Google Scholar

Shi, B. et al. Two-step regulation of a meristematic cell population acting in shoot branching in Arabidopsis. PLoS Genet. 12, e1006168 (2016).

Article PubMed PubMed Central Google Scholar

Hao, C. et al. Resequencing of 145 landmark cultivars reveals asymmetric sub-genome selection and strong founder genotype effects on wheat breeding in China. Mol. Plant 13, 17331751 (2020).

Article CAS PubMed Google Scholar

Bisht, A. et al. PAT1-type GRAS-domain proteins control regeneration by activating DOF3.4 to drive cell proliferation in Arabidopsis roots. Plant Cell https://doi.org/10.1093/plcell/koad028 (2023).

Fan, M., Xu, C., Xu, K. & Hu, Y. LATERAL ORGAN BOUNDARIES DOMAIN transcription factors direct callus formation in Arabidopsis regeneration. Cell Res. 22, 11691180 (2012).

Article CAS PubMed PubMed Central Google Scholar

Schulze, S., Schfer, B. N., Parizotto, E. A., Voinnet, O. & Theres, K. LOST MERISTEMS genes regulate cell differentiation of central zone descendants in Arabidopsis shoot meristems. Plant J. 64, 668678 (2010).

Article CAS PubMed Google Scholar

Wang, F. X. et al. Chromatin accessibility dynamics and a hierarchical transcriptional regulatory network structure for plant somatic embryogenesis. Dev. Cell 54, 742757 (2020).

Article CAS PubMed Google Scholar

Xu, M., Du, Q., Tian, C., Wang, Y. & Jiao, Y. Stochastic gene expression drives mesophyll protoplast regeneration. Sci. Adv. 7, eabg8466 (2021).

Article CAS PubMed PubMed Central Google Scholar

Bie, X. M. et al. Trichostatin A and sodium butyrate promotes plant regeneration in common wheat. Plant Signal. Behav. 15, 1820681 (2020).

Article PubMed PubMed Central Google Scholar

Jiang, F. et al. Trichostatin A increases embryo and green plant regeneration in wheat. Plant Cell Rep. 36, 17011706 (2017).

Article CAS PubMed Google Scholar

Zhao, N. et al. Systematic analysis of differential H3K27me3 and H3K4me3 deposition in callus and seedling reveals the epigenetic regulatory mechanisms involved in callus formation in rice. Front. Genet. 11, 766 (2020).

Article CAS PubMed PubMed Central Google Scholar

Daimon, Y., Takabe, K. & Tasaka, M. The CUP-SHAPED COTYLEDON genes promote adventitious shoot formation on calli. Plant Cell Physiol. 44, 113121 (2003).

Article CAS PubMed Google Scholar

Zhai, N. & Xu, L. Pluripotency acquisition in the middle cell layer of callus is required for organ regeneration. Nat. Plants 7, 14531460 (2021).

Article CAS PubMed Google Scholar

Liu, W. et al. Transcriptional landscapes of de novo root regeneration from detached Arabidopsis leaves revealed by time-lapse and single-cell RNA sequencing analyses. Plant Commun. 3, 100306 (2022).

The rest is here:
Uncovering the transcriptional regulatory network involved in ... - Nature.com

Oncopeptides AB – Invitation to presentation of the Q1 report 2023 – Marketscreener.com

By Stell Cell Research

Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on May 4.

Investors, financial analysts, and media are invited to participate in a webcast and a following QnA session on May 4 at 09:00 (CET). The presentation will be hosted by Monica Shaw, CEO, together with Holger Lembrer, CFO, and will be held in English. It will be published on the website of Oncopeptides in conjunction with the start of the presentation.

Information for participants

If you wish to participate in the webcast, please use the link below. Through the webcast you will have opportunities to ask written questions to the company's leadership.

If you wish to participate via teleconference, please register on the link below. After the registration you will be provided with a phone number and a conference ID to access the conference. You can ask questions to the leadership verbally via the teleconference.

Contact:

Rolf Gulliksen

Email: rolf.gulliksen@oncopeptides.com

Tel: + 46 70 262 96 28

About Oncopeptides

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO.

(C) 2023 Electronic News Publishing, source ENP Newswire

See the rest here:
Oncopeptides AB - Invitation to presentation of the Q1 report 2023 - Marketscreener.com

Join the Autism Summit For Parents Free Virtual Talks to Cover … – GlobeNewswire

By Stell Cell Research

London, May 01, 2023 (GLOBE NEWSWIRE) -- London, England -

Autism Parenting Magazine Ltd. will be hosting its Autism Conference in May, continuing to bridge the ever-growing gap between autism experts and special needs families.

Autism Parenting Magazine (APM) is an award-winning publication aimed at improving the quality of life for families affected by autism. For over a decade, APM has been at the forefront of bringing special needs families from around the world together and disseminating invaluable information on the latest interventions and treatments for autism. Today, it has become an essential resource for parents around the world.

APM will soon be hosting its annual Autism Summit For Parents featuring some of the leading experts in the study and management of autism. At least 30 keynote sponsors and speakers will be presenting valuable insights on treatments, interventions, and support strategies.

The event will take place between 12 15 May 2023 and will be hosted online, thus saving families the time and costs related to travel and accommodation. Parents and family members are encouraged to join the event's global audience of some 25,000 attendees and be part of the growing community.

The Autism Conference will offer parents caring for children on the spectrum the opportunity to meet experts in different areas of the autism world. The Summit will benefit the entire autism communityparents, family members, allies, caregivers, and people on the spectrum will find inspiration and gain knowledge from this event.

Interested parties only need to visit APMs website and register for the free pass.

For more information, visit https://autismparentingsummit.com/

The Autism Summit 2023 will have much to offer parents and caregivers as a panel of notable keynote speakers will be explaining cutting-edge concepts based on the latest technologies science has to offer.

Dr. Neil Riordan is one of the early pioneers and experts in applied stem cell research and the founder and chairman of Medistem Panama, Inc., a leading stem cell laboratory and research facility. He is also the founder, chairman, and chief science officer of the Stem Cell Institute in Panama, specializing in the treatment of human diseases and conditions with adult stem cells.

Dr. Gabriel Belfort is the senior vice president of Clinical Development Sciences and Operations at Axial Therapeutics. A physician-scientist focusing on exploring molecular, cellular, and pre-clinical pharmacological aspects of central nervous system function, he serves as the medical director accelerating the clinical development of high-quality novel therapeutics.

Carmellina Stetson is the clinical director of Blue Balloon ABA, North Carolina with a masters degree in Applied Behavior Analysis with a concentration in Autism Studies. Stetson has extensive experience developing programs for individuals with ASD, valuing all individuals learning styles and preferences in order to help each individual reach the highest potential.

Dr. Erik Won is the president & chief medical officer of Wave Neuroscience, a biotechnology company developing innovative solutions to optimize brain function, including autism spectrum disorder. Wave technologies utilize computational neuroanalytics and brain imaging to customize treatment protocols with the aim of restoring optimal neurological function.

Dr. Theoharis Theoharides, a Professor of Pharmacology for 40 years and presently a professor at an institute of neuroImmune medicine, has received multiple awards for his work as well as his humanitarian efforts. He has published myriad scientific papers on neural conditions, including autism spectrum disorder, and has helped formulate unique dietary supplements with over 37 patents and trademarks, including some covering the use of luteolin in autism.

Over the four-day Autism Summit For Parents, these highly acclaimed individuals will be joined by 25 other experts who will speak on a wide range of topics that matter most to special needs families.

About the Publication:

Founded by Mark Blakey, Autism Parenting Magazine is the leading publication for parents of autistic children with an international following. The online magazine has expanded and now offers virtual summits and courses for parents that struggle with special needs children. Daily, the people at Autism Parenting Magazine inspire and entertain its global audience through social media posts. By providing informative content and autism resources, its goal is to improve the quality of life of families affected by autism.

###

For more information about Autism Parenting Magazine, contact the company here:

Autism Parenting MagazineMark Blakey+44(0)203 290 9176press@autismparentingmagazine.comKemp House, 160 City Road, London, EC1V 2NX, United Kingdom

Continued here:
Join the Autism Summit For Parents Free Virtual Talks to Cover ... - GlobeNewswire

Be the Match nonprofit saves woman’s life through stranger’s stem cell transplant – WABC-TV

By Stem Cell Doctors

LOWER MANHATTAN, Manhattan (WABC) -- The ultimate story of kindness resulted in an emotional meeting between a young man from New Jersey and a woman from North Carolina, who is alive today because he supplied her with a stem cell transplant to help her fight leukemia.

At a fundraising benefit in a downtown ballroom, two strangers were about to meet, but it wouldn't be just any meeting. "I don't think I'll even be able to speak when I meet him," Debbie Giroux said.

Giroux was about to meet the man who saved her life.

HOW TO BECOME A BONE MARROW DONOR: Be The Match

"Oh, I think it's going to be pretty emotional," Ryan Keegan said. "We're an emotional family. I didn't want to cry in front of everyone but I think the tears will be flowing."

When his father was diagnosed with leukemia, Keegan became a stem cell donor to help his dad or anyone else suffering from blood cancers.

ALSO READ | SNEAK PEEK: American Museum of Natural History opening state-of-the-art science center

American Museum of Natural History in NYC to open new science center

With a cheek swab, he joined the registry at the nonprofit, Be the Match. And he was.

"It's very surreal because you know that if you don't find that match, you're not going to survive," Giroux said.

Doctors harvested his stem cells at a lab near his home in Howell, New Jersey, and a few months later, they found their way to Charlotte, North Carolina and into Giroux's blood, giving her a second chance at life.

"This year alone we'll save over 7,000 lives, and since our inception, almost 130,000 lives have been saved," said Be the Match CEO Amy Ronneberg.

Be the Match doesn't just run the registry, it also helps families cover their steep costs during the year it can take to recover after a bone marrow transplant.

"I think we're living proof that this works and join the registry and make the difference, you can save someone's life," Keegan said.

----------* Get Eyewitness News Delivered * More Manhattan news* Send us a news tip* Download the abc7NY app for breaking news alerts * Follow us on YouTube

View original post here:
Be the Match nonprofit saves woman's life through stranger's stem cell transplant - WABC-TV

Doctor’s Tip: How to prevent and survive breast cancer – Glenwood Springs Post Independent

By Stem Cell Doctors

Breast cancer is the number one type of cancer in the U.S, aside from skin cancer. Every year, around 280,000 women are diagnosed with it and some 43,000 die from it.

Some of the billions of cells in our bodies are always mutating. Mammograms and self-breast exams are said to provide early detection of breast cancer, but Dr. Michael Greger points out that this is actually late detection, because by the time breast cancer is diagnosed by these methods it has been present for years, starting with the first abnormal cell. Humans evolved to eat plants, and plants contain micronutrients that destroy mutant cells before they propagate and cause cancer; animal products lack this ability.

If you are a woman and want to do everything you can to prevent breast cancer, read the chapter on breast cancer in Dr. Gregers book How Not to Die, and search breast cancer on his website nutritionfacts.org. If youre a breast cancer survivor, read The Cancer Survivors Guide, Foods That Help You Fight Back! by Neal Barnard, M.D.

Following are some important tips to prevent breast cancer, found in these two books plus an article in the January/February issue of Nutrition Action titled, Cancer, How to Lower Your Risk.

Alcohol, even in small amounts, was declared in 2014 by the World Health Organization to be a definitive human breast carcinogen, due to DNA damage, oxidative stress, and increase in estrogen levels.

Melatonin, the sleep hormone, appears to have a protective effect against breast cancer. Melatonin levels are lowered by bright lights during pre-bedtime hours from sources such as light bulbs, TV screens, computers and smart phones. For unknown reasons, eating meat lowers melatonin levels and vegetables raise them.

Estrogen in excess increases breast cancer risk, and women need to be hesitant about taking post-menopausal hormones bio-identical hormones have not been shown to be any safer. Fat cells produce estrogen, so to avoid breast cancer its important to maintain ideal body weight.

Saturated fat present in animal products, cooking oils and coconut products (other than coconut water) increases breast cancer risk.

Exercise, such as brisk walking for at least 30-60 minutes every day, lowers breast cancer risk due to loss of excess fat and lower levels of inflammation.

Heterocyclic Amines (HCAs) are carcinogens produced by cooking meat (including chicken) and seafood at high temperatures, such as roasting, pan frying, grilling, and baking. According to Dr. Greger, One of the most abundant HCAs in cooked meat was found to have potent estrogen-like effects, fueling human breast-cancer cell growth.

Lignans are plant estrogens (a.k.a. phytoestrogens) activated by good gut bacteria, that dampen the effects of the bodys own estrogen, according to Dr. Greger. Lignans are particularly plentiful in flaxseeds, and are also found in berries, whole grains and dark, leafy greens.

Cholesteral, when levels are high, may increase breast cancer risk, according to Dr. Greger thought to be due to our bodies using cholesterol to make estrogen or to shore up tumor cell membranes to help the cancer migrate and invade more tissue. Unfortunately, reducing levels with statin drugs has not been shown to reduce breast cancer risk.

Fiber present in plant but not animal products helps remove estrogen via the GI tract, thereby lowering breast cancer risk. Several studies show that for every 29 grams of fiber intake per day there is a 15% lower risk of breast cancer.

Carotinoids are micronutrients found in green, orange and red fruit and vegetables and have been found to protect against breast cancer. Apple peels in particular contain a compound that activates breast tumor-suppressor genes.

Sulforaphane, a compound in cruciferous vegetables (like broccoli, cabbage, kale, cauliflower) suppresses the ability of breast cancer stem cells to form tumors the cause of recurrence of breast cancer that occasionally happens after years of remission. Cooking destroys the enzyme that releases sulforaphane, so some needs to be eaten raw or eat some raw cruciferous vegetables before eating cooked.

Soy? Many people have the misconception that soy contains estrogen and should therefore be avoided to prevent breast cancer. The fact is that if the weak, estrogen-like compounds in soy attach to breast tissue receptors, stronger, harmful estrogens are prevented from attaching, resulting in a lower risk of breast cancer. Asian women eat a diet high in soy products, and have much lower risk of breast cancer compared to women on a typical Western diet.

Dr. Feinsinger is a retired family physician with special interest in disease prevention and reversal through nutrition. Free services through Center For Prevention and The Peoples Clinic include: one-hour consultations, shop-with-a-doc at Carbondale City Market, and cooking classes. Call 970-379-5718 for appointment, or emailgfeinsinger@comcast.net.

Continued here:
Doctor's Tip: How to prevent and survive breast cancer - Glenwood Springs Post Independent

All You Need to Know about a Bone Marrow Transplant – Metropolis Healthcare

By Stem Cell Doctors

What is a Bone Marrow Transplant?

A bone marrow transplant is a medical procedure for patients with certain cancers and other diseases such as severe aplastic anaemia, immune deficiency disorders, etc. Bone marrow is a spongy material present inside the bones which produces and stores blood cells. The transplantation of blood stem cells replaces damaged bone marrow with functioning, healthy bone marrow; rejuvenates the immune system to fight back the diseased or damaged cells; and assists in the smooth recovery of the patient.

At a young stage, your blood cells are called hematopoietic stem cells. After maturing they travel into your blood from your bone marrow, therefore a bone marrow transplant is also called a stem cell transplant.

A bone marrow transplant involves taking stem cells from your bone marrow, then filtering those cells and then giving these filtered stem cells back to the donor or to another person.

The main aim of a bone marrow transplant is to infuse healthy bone marrow cells into a person. Since,1998 this procedure has been used to successfully treat diseases such as aplastic anaemia, immune deficiency disorder, lymphomas, leukemias and some solid tumor cancers.

Bone marrow transplant is done to cure many types of cancer and some other diseases. Often to cure cancer, the doses of chemotherapy that a patient is subjected to are quite high and this high-frequency radiation can permanently damage or destroy the stem cells in the bone marrow therefore, a transplant may be needed.

In some cases, the stem cells in the bone marrow are already damaged by the occurrence of a disease and so a transplant is needed.

A bone marrow transplant may help you by:

The risks and benefits must be weighed in a thorough discussion with your healthcare emphasising why a Bone Marrow Transplant.

Following are the examples of the most common diseases that may benefit from a bone marrow transplant:

Doctors are also able to perform anumbilical cord blood transplant where stem cells are collected from the umbilical cord immediately after the delivery of an infant. These stem cells can reproduce into mature, functioning blood cells quicker and more effectively than the stem cells taken from the bone marrow of another child or adult. These stem cells are tested, typed, counted, and frozen until they are needed for a transplant.

Only your doctor can decide whether or not a bone marrow transplant is the best course of action for you. With a physical examination and multiple tests, your doctor will be able to talk to you about what type of procedure is your best bet and what you can expect.

If your doctor and you reach a common ground and decide to go ahead with a bone marrow transplant, finding a donor will start after matching your bone marrow transplant will be finalised.

A few days before the transplant your doctor will put a tube called a central venous catheter into a vein in your chest. Your doctor along with your medical team will use it to take blood and give you medicine and It will stay there until after your treatment.

A bone marrow transplant is a widely accepted, associated medical procedure for certain types of cancer and other diseases that could damage or destroy the bone marrow of a patient. The transplanting of blood stem cells has pronged applications to produce new blood cells, promote new marrow growth, and regenerate the immune system. This as well promotes patient recovery and survival rates.

However, continuous follow-up care is essential for the patients. Also, a pre-procedure discussion with a healthcare provider and specialists in bone marrow transplants is advisable to learn the risks and benefits. Metropolis Healthcare is a leading pathology lab and diagnostic centre with a multinational network, a comprehensive range of 4000+ clinical laboratory tests and profiles, and senior pathologists to deliver diagnostic solutions. They offer the convenience of a stay-at-home blood collection service, online tracking of samples, and report download from a single app.

They are widely recognized by several brands and institutions and offer a comprehensive Corporate Social Responsibility program. Bone marrow transplant is a boon to many patients and new methods and diagnoses to improve treatment options and decrease complications and side effects are continually being discovered.

LikeLoveHahaWowSadAngry

Go here to read the rest:
All You Need to Know about a Bone Marrow Transplant - Metropolis Healthcare

Chicago Med Season 8 Episode 19 Review: Look Closely And You … – TV Fanatic

By Stem Cell Doctors

Hospital politics are always messy. Even when no corporate overlord is trying to steer the institution in a direction that might not be best for patients, board members often clash with healthcare providers.

Chicago Med Season 8 Episode 19 is the latest medical drama to explore what happens when a non-doctor with their own agenda gains a controlling interest in the hospital (both The Good Doctor and New Amsterdam offered similar stories in 2022).

Jack seemed all right as a hospital owner -- until he wasn't. But his latest victory was utterly predictable.

With all the noise Sharon, George, and Will kept making about how Vernon would swing the vote their way, how could he not betray them at the last second?

Will went to a ton of trouble to ensure Vernon could vote while Jack tried his hardest to interfere -- only for Vernon to gain a new perspective after his surgery.

Surprise! NOT. Vernon hadn't considered the issue before falling ill; he only went along with Sharon because he'd been on the board for 23 years and trusted her opinion.

Although Vernon came through the surgery fine, thanks to OR 2.0 and Abrams' surgical skills, I'd think he'd need more than an hour in the recovery room before he could sit through a board meeting, even by video. The man just had brain surgery!

Television brain tumor survivors often wake up with drastically different personalities, so it was likely that Vernon would support Jack for that reason. The only twist was that 2.0's saving his life made him decide that Jack's vision for the hospital was the way to go.

I don't know George and Sharon's counterarguments, but they allowed Jack to frame the discussion in a way that benefited his position. Why is going to for-profit status the only way to ensure Gaffney continues offering cutting-edge medical technology?

Instead of arguing that for-profit status is contrary to the hospital's established mission, which board members didn't appear to care about, the counterargument should have focused on for-profit status being unnecessary to achieve the goal of being a leader in the medical tech sector.

They could have focused on the idea that Gaffney could be that leader AND continue to provide care to all patients, regardless of income level.

This missed opportunity will change Gaffney forever -- or at least until the board votes to repeal the for-profit status. But the irony of Will's plan causing the opposite result of what he wanted was SO delicious!

Grace balked at Will asking for her expertise when it meant that Jack's proposal might be defeated, but will she change her tune now that Vernon votes for the plan?

What Will did wasn't entirely unethical.

Yes, getting Vernon's wife to agree to surgery meant Vernon could participate in the board meeting. But Vernon needed the surgery anyway; he had to be intubated, with no guarantee that the alternative treatment would do anything to resolve his tumor.

Grace might have felt used, but she DID help Vernon get the needed treatment, so there was that.

Archer's behavior was a lot more questionable. At least half the reason he broke Kira's confidentiality was to get back at Asher for telling Sean about Archer's medical condition.

He gave her a BS explanation about Kimberly being Kira's proxy if something went wrong during surgery, but come on. Every other word out of his mouth was about how now Asher believed in confidentiality when she didn't before.

This petty behavior and refusal to recognize patients' rights made me hate Archer when he arrived at Med. He's been more tolerable lately and, in some ways, more relatable.

But not this time. He was wrong to violate Kira's confidentiality, and even if Asher was wrong to break his, that's no excuse. Didn't Archer learn that two wrongs don't make a right long before he was old enough for medical school?

The Kira situation was surprisingly opposite of what I expected.

When Chicago Med Season 8 Episode 19 spoilers stated that Asher and Archer would be dealing with a stem cell disease and a pregnant daughter, I predicted that the mother would want her daughter to give up the baby so that she could use its stem cells.

That would have been a fascinating ethical dilemma, but the actual story was fantastic. Still, I wondered why the doctors couldn't use the stem cells from the non-viable fetus to cure Kimberly's disease, assuming they were a match.

I'm glad that Marcel helped Tanaka-Reid get his self-confidence back.

I could have done without most of this story, which featured a bunch of residents acting like high school students. The teasing and bullying were inappropriate behavior. Tanaka-Reid acted like the stereotypical nerdy kid who pretends not to care but secretly fears his bullies are right to tease him.

Marcel was right that the other residents were reacting to Tanaka-Reid acting like he was far superior for the last year or so, but again -- two wrongs don't make a right. And in this case, there was far too much immature behavior for my liking.

At least Marcel and Tanaka-Reid have settled into a more respectful mentor/mentee relationship! Tanaka-Reid was insufferable when he used to try to replace Marcel's judgment with his own.

Charles' main story was interesting. I liked that Maggie could interpret ASL so that they could catch Sandy making up stories about what her brother was communicating.

Aiden's desire to keep the imaginary voices in his head because he could HEAR them was also interesting, and I wish there'd been more time to develop that part of the story.

And what was with Lilian's obnoxious brother? Charles went from one language barrier to another in that last scene, and Pavo did nothing to endear himself to viewers. I wondered if he thinks Charles is too good for Liliana or believes a doctor must have an ulterior motive for dating his sister.

Your turn, Chicago Med fanatics! Hit the big, blue SHOW COMMENTS button and let us know your thoughts.

Don't forget you can watch Chicago Med online on TV Fanatic.

Chicago Med airs on NBC on Wednesdays at 8/7c.

Edit Delete

Jack Ori is a senior staff writer for TV Fanatic. His debut young adult novel, Reinventing Hannah, is available on Amazon. Follow him on Twitter.

Read more:
Chicago Med Season 8 Episode 19 Review: Look Closely And You ... - TV Fanatic

Mum put on life support after infected finger led to ‘devastating … – The Independent

By Stem Cell Doctors

Stay ahead of the trend in fashion and beyond with our free weekly Lifestyle Edit newsletterStay ahead of the trend in fashion and beyond with our free weekly Lifestyle Edit newsletter

A mother-of-three who noticed her finger had become infected as it was all swollen and green and was put in an induced coma after a devastating leukaemia diagnosis which left her battling for life has said it was never an option to give up.

Now celebrating being almost six years cancer-free, Peppie Scobbie, 53, who lives in Larkhall, South Lanarkshire, said she did not feel right while holidaying in Portugal in July 2017 after which she returned home and noticed her finger had gone green and was swollen and throbbing.

After antibiotics failed to treat the apparent infection, she was diagnosed with acute myeloid leukaemia (AML) a type of blood cancer aged 47, and underwent three intense rounds of chemotherapy, which made her hair fall out in clumps.

During the first round of treatment, Peppie developed pneumonia and sepsis and was put in an induced coma and on life support, which made doctors question whether she was going to make it.

Amazingly, Peppie bounced back, completed all three rounds of chemotherapy, and was told she was cancer-free just before Christmas in 2017.

Peppie then received a stem cell transplant from her older brother Tom McClure in January 2018 a form of treatment for certain types of cancer as she knew that if she did not have this, she would relapse and die.

Thanks to her treatment, she was able to marry Stevie, a 51-year-old foreman, in 2020, and her brother-turned-donor Tom walked her down the aisle.

Now, despite being told she will be in chronic pain for the rest of her life and suffering with severe side effects as a result of her medication, she will soon celebrate being six years cancer-free and wishes to share the message that theres light at the end of the tunnel.

I have days where I could cry, Peppie said.

I could lie in my bed at night and cry because it upsets me, and I always say, Why me? Why did this have to happen to me?

But I want to be here and live a life as best I can, considering whats against me.

It was never an option for me to give up; it never ever has been and never ever will be.

Peppie first noticed she didnt feel (herself) during a holiday in Portugal in July 2017.

(PA Real Life)

After returning home and resuming work with her cleaning business, from which she has since retired, Peppie said a clients dog jumped on her arm and it felt like an electric shock.

Her arm went black and blue within a matter of hours, which she thought was strange but initially didnt think anything of it, however, this soon changed.

I dragged myself out my bed every morning to go to work, but I was screaming inside because I just knew there was something not quite right with me, Peppie said.

Peppie then noticed the skin on the middle finger of her left hand had become infected.

The finger was throbbing but three courses of antibiotics prescribed by her GP did nothing to alleviate the symptoms.

On August 16 2017, Peppie underwent blood tests and the following day she received a phone call from her doctor saying she had a high white blood cell count and low haemoglobin levels.

Just 30 minutes later, she received a second call and was told she had leukaemia.

She said she was devastated.

I felt physically sick, Peppie said.

You just read about things like that, and you hear it about other people, but you dont expect to hear that about yourself.

It was a bit surreal.

Peppies brother Tom, walking her down the aisle

(PA Real Life/Gallery Eleven Photography)

On August 18, the day after receiving the news, it was confirmed Peppie had AML and she began her first round of chemotherapy.

Peppie said she did not have time to process her thoughts as her brain went numb, but the only question she had in her mind at that time was am I going to survive this?

I just kept thinking, am I going to die? Peppie continued.

Then I thought, no, dont put that in your head, because if I start thinking thoughts like that then its just going to consume me and its going to bring me down.

I tried not to think about the bad side of things, I tried to be positive.

However, after starting chemotherapy Peppie said she began to develop a temperature.

She was taken to the high-dependency unit where she lost consciousness, before being moved to the intensive care unit (ICU) at University Hospital Monklands where she was put in an induced coma and placed on life support for two weeks.

It was later discovered she had developed pneumonia and sepsis.

Peppie was visited by her family during this time, and doctors did not know whether she was going to make it, but thankfully, the will and the fight was there.

I was told about a week afterwards that not many people survive and come back up the stairs the way I did, Peppie said.

Peppie then started her second and third rounds of chemotherapy, and while she did not have any major complications, the medication she was taking made her hallucinate and she lost her hair.

This led to her shaving her head, which was a hard pill to take.

I couldnt even look in the mirror because all I could see was this person that had cancer, who was ill, and it took me a long time to see past that person, she said.

By Christmas, Peppie was told she was in remission, which was the best outcome, and she was able to spend time with her family and now-husband.

She was also told that her older brother Tom McClure was the perfect match for a stem cell transplant, and she received this in January 2018.

She had another transplant in June, but was then diagnosed with graft versus host disease where white blood cells attack the patients own body causing severe illness and damage to the skin on her feet and hands.

After recovering from this, Peppie married Stevie on February 14 2020, and Tom walked her down the aisle, as their father, Thomas, had passed away from pulmonary fibrosis in 2015.

She said she couldnt think of anyone better to stand in for her dad.

Although Peppie is now nearly six years cancer-free, she is still taking numerous medications, including immunosuppressive drugs and steroids.

As a result of taking steroids, Peppie said her gut and mouth have been permanently affected and she develops ulcers; she has avascular necrosis, which affects blood supply to the bone; she has undergone two knee replacements; and she has been diagnosed with osteoporosis a condition that weakens bones.

She also has blood tests every fortnight and recently underwent two blood transfusions.

Although she is in pain every single day, she still goes to aqua-fit classes three times a week, sees her friends, and walks her two dogs, Lily and Cooper.

The grandmother-of-five said her family keep her strong because they mean everything to me, and she hopes that she can offer a glimmer of hope to those going through cancer treatment by sharing her story.

Im five years post-transplant and Im still here, Im still living my life, she said.

Its maybe not the best quality life most days it is but youve just got to cling on to that hope and that positivity to get you there, and obviously have good family and friends to help you achieve that.

Theres light at the end of the tunnel.

Leukaemia UK is investing in life-changing research into more effective treatments for AML and other types of blood cancer. For more information, visit: leukaemiauk.org.uk

More here:
Mum put on life support after infected finger led to 'devastating ... - The Independent

Fecal Transplant Pill Approved for Recurrent C. Diff Infection – Everyday Health

By Stem Cell Doctors

The first ever pill that mimics the effects of fecal transplants was approved on April 26, 2023, by the U.S. Food and Drug Administration (FDA). The treatment, called Vowst, is created with healthy bacteria from screened fecal donations, and is used to prevent the recurrence of C. difficile(C. diff) infection (CDI) in adults following antibacterial treatment for recurrent CDI.

Todays approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection, said Peter Marks, MD, PhD, the director of the FDAs Center for Biologics Evaluation and Research, in the FDA statement.

The availability of a fecal microbiota product that can be taken orally is a significant step forward in advancing patient care and accessibility for individuals who have experienced this disease that can be potentially life-threatening, said Dr. Marks.

CDI, caused by the bacterium C. difficile, is one of the most common healthcare-associated infections, and results in severe nausea, cramping, and diarrhea.

When the community of microorganisms inhabiting the gut and supporting our health is disturbed with antibiotics usually prescribed for the treatment of unrelated medical issues C. difficile can expand in numbers and produce toxins that can damage the lining of the large gut, says Niaz Banaei, MD, a professor of pathology and infectious diseases at Stanford Medicine in Palo Alto, California, who was not involved in the development of Vowst.

This can lead to symptoms such as diarrhea and gut inflammation, and even death if not treated appropriately, says Dr. Banaei. Approximately 15,000 to 30,000 people die from the infection each year.

Unfortunately, this disease process can recur because key members of the gut microbial community have vanished, he says. Besides taking antibiotics, other risk factors for recurrent CDI include:

Fecal microbiota transplant restores the gut microbial community back to a healthy state and reverses the pathologic state that occurred as a result of the disruption, he says.

More than 10 years ago, doctors began successfully treating recurrent CDI with fecal transplants, a procedure that involves taking healthy bacteria from the feces of a screened donor and transferring them to the colon of the recipient, typically through a colonoscopy.

Fecal microbiota transplant has been shown to be highly effective in restoring the gut microbiota and preventing recurrence of CDI, says Banaei.

The Vowst treatment aims to offer those same benefits restore the gut flora to prevent further episodes of CDI but via oral capsules. Carefully screened donations plus rigorous manufacturing and quality control are all part of producing the capsules, says Carlo Tanzi, PhD, the head of investor relations and corporate communications for Seres Therapeutics, the manufacturer of Vowst.

After the stool samples are collected and tested, the samples are processed to remove the waste, isolate the healthy bacteria, and kill any other lingering organisms. Thousands of capsules can be made from each stool sample, making it a more efficient process than current fecal transplants, according to the company.

FDA approval was based on a phase 3 study published January 20, 2022, in theNew England Journal of Medicine. Of the 182 participants, 88 percent who took the capsules did not experience reinfection after eight weeks, compared with 60 percent of those who received placebo. At six months post-treatment, 79 percent of the Vowst group were recurrence-free, compared with 53 percent in the placebo group.

The FDA approval of fecal capsules will simplify restoration of the gut microbiota and will make the intervention more accessible, says Banaei.

This is an important advancement for those who suffer from the estimated nearly 156,000 episodes of recurrent CDI in the United States each year, says Dr. Tanzi. These patients often suffer debilitating symptoms, like frequent diarrhea up to 15 times a day, which prevent them from participating in their normal daily activities. Patients often are unable to leave the house, go to work, and spend uninterrupted time with loved ones, he says.

In the clinical trials, recipients experienced some side effects acutely, including abdominal bloating, fatigue, constipation, chills, and diarrhea, but overall, the intervention did not raise any safety concerns, says Banaei.

Vowst may carry a risk of transmitting infectious agents, according to the FDA statement. It is also possible for Vowst to contain food allergens, the agency noted.

The dosing regimen of Vowst is four capsules taken by mouth once a day, for three consecutive days. The therapy is expected to be available beginning June 2023, according to the product website.

The list price for Vowst is $17,500, according to a company presentation. The actual cost to consumers will depend on insurance coverage.

It will be interesting to see if other patient populations with disrupted gut microbiota but with nonC. diffdiarrhea also benefit from Vowst, says Banaei.

The makers of Vowst believe there may be more opportunities to create new treatment modalities through the microbiome not just in recurrent CDI, but in additional therapeutic areas where the microbiome has a direct connection to human health.

According to Tanzi, the company is continuing to investigate new products, including an investigational therapy designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia, and graft-versus-host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).

Follow this link:
Fecal Transplant Pill Approved for Recurrent C. Diff Infection - Everyday Health

→←